"A particular focus is on treatment of patients on opioids, since discogenic back pain accounts for approximately 50% of prescription opioid usage in the US. • Significant pain reduction and opioid cessation were observed in Mesobloblast's first phase 3 trial"
I as a large shareholder cannot emphasize enough the significance of the above statistic .
50% ...
In a country that has an opioid epidemic and the sufferers initiation and / or introductions to opioids, for the most part, being scripts for pain, then any alternative that steers patients away from such insidious and destructive addictive substances will be nothing less that miraculous and I trust that MSB shareholders ( large and small ) are fully aware of what's going on here because I certainly am.
It usually starts with Oxycodone and usually doesn't end very well at all, if at all !
GLTLH
Molly
MSB Price at posting:
$1.32 Sentiment: Buy Disclosure: Held
A personalised tool to help users track selected stocks. Delivering real-time notifications on price updates, announcements, and performance stats on each to help make informed investment decisions.
(20min delay)